Novartis(US:NVS) Zhi Tong Cai Jing·2025-08-05 13:11Core Viewpoint - Novartis (NVS.US) has registered a Phase III clinical trial for inclisiran aimed at evaluating its efficacy and safety in patients with acute coronary syndrome (ACS) during early hospitalization [1] Group 1: Clinical Trial Details - The trial is a multicenter, randomized, double-blind, placebo-controlled study involving patients who have recently experienced ACS, including ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI) [1] Group 2: Drug Background - Inclisiran is the first approved PCSK9siRNA drug globally, receiving approval from the EU and FDA in 2020 and 2021 for the treatment of adult hypercholesterolemia and mixed dyslipidemia, demonstrating the therapeutic potential of small nucleic acid drugs in chronic disease management [1] - To date, inclisiran has been approved for four indications in the EU, three indications in the US, and four indications in China [1]